Compare · BSX vs KIDS
BSX vs KIDS
Side-by-side comparison of Boston Scientific Corporation (BSX) and OrthoPediatrics Corp. (KIDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and KIDS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $70.11B, about 153.1x KIDS ($458.0M).
- Over the past year, BSX is down 52.3% and KIDS is down 17.6% - KIDS leads by 34.8 points.
- Both names hit the wire about 12 times in the past 4 weeks.
- BSX has more recent analyst coverage (25 ratings vs 8 for KIDS).
- Company
- Boston Scientific Corporation
- OrthoPediatrics Corp.
- Price
- $47.03-0.31%
- $18.00+0.87%
- Market cap
- $70.11B
- $458.0M
- 1M return
- -11.46%
- +1.64%
- 1Y return
- -52.35%
- -17.57%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 12
- 12
- Recent ratings
- 25
- 8
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest KIDS
- Director Pelizzon David R was granted 11,436 shares, increasing direct ownership by 35% to 44,384 units (SEC Form 4)
- Director Fischer Kelly Laine was granted 11,436 shares, increasing direct ownership by 263% to 15,781 units (SEC Form 4)
- Director Ruf Harold was granted 11,436 shares, increasing direct ownership by 136% to 19,837 units (SEC Form 4)
- Director Hughes Bryan W was granted 11,436 shares, increasing direct ownership by 54% to 32,663 units (SEC Form 4)
- Director Riccitelli Samuel D was granted 11,436 shares, increasing direct ownership by 56% to 31,859 units (SEC Form 4)
- Director Dyer George Sinclair Mitchell was granted 11,436 shares, increasing direct ownership by 87% to 24,568 units (SEC Form 4)
- Director Mcdonald Jimmy Duane was granted 11,436 shares, increasing direct ownership by 87% to 24,568 units (SEC Form 4)
- Director Throdahl Mark C was granted 11,436 shares, increasing direct ownership by 7% to 179,317 units (SEC Form 4)
- President and CEO Bailey David R was granted 119,140 shares, increasing direct ownership by 40% to 417,160 units (SEC Form 4)
- Director Infante (Reynolds) Marie C was granted 11,436 shares, increasing direct ownership by 58% to 31,202 units (SEC Form 4)